MaxCyte Minutes Newsletter – April 2023
We are pleased to announce that MaxCyte, Inc. has officially launched a refresh of our brand! This new look and feel embodies our patient-inspired mindset – that MaxCyte exists to maximize the potential of cells to improve lives and that we are in this together with you.
We recognize that you need more than just technology to achieve your goals – you need the right tools, ongoing technical expertise, and regulatory support to succeed. We’ve spent more than 20 years honing our cell engineering expertise — building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today’s processes to innovate tomorrow’s solutions. And we offer you all of it so that we can build better cells together to ultimately help more patients.
As we chart the best course together using this refreshed brand, we encourage you to visit our website to learn more.
Kind regards, Doug Doerfler, CEO
IN THE NEWS
MaxCyte® Establishes New Scientific Advisory Board Comprised of Globally Recognized Experts in Cell Engineering Enabling Technology
MaxCyte welcomes four dynamic scientists to our Scientific Advisory Board: Oliver Rando, Marcela Maus, Avery Posey, Jr., Ph.D., and Nako Nakatsuka, Ph.D.
“With the formation of our Scientific Advisory Board, we are expanding the depth and breadth of our leadership team and scientific expertise with the next generation of leaders in the field of gene and cell therapy,”
- MaxCyte CEO Doug Doerfler.
Strategic Partnerships News
We are thrilled to announce the signing of a strategic partnership with Catamaran Bio, a company focused on developing novel off-the-shelf chimeric antigen receptor (CAR)-NK cell therapies to treat a broad range of cancers.
We are honored to help Catamaran Bio further their CAR-NK cell therapy programs with our Flow Electroporation® technology and ExPERT™ platform. This collaboration marks a pivotal milestone in the quest in developing innovative solutions for complex diseases like cancer.
Decoupling Electroporation Buffer from RUO Processing Assemblies
We would like to remind you that we will no longer automatically include electroporation buffer with RUO processing assemblies. This change addresses customers’ requests to help reduce waste and alleviate storage issues, and aligns with our Corporate Responsibility efforts toward environmental sustainability.
Our proprietary electroporation buffer is available in 100 mL and 500 mL bottles, and in 500 mL and 1 liter bags.
Webinar: Memory-rich CAR-T cell engineering by piggyBac transposon system for solid malignancies
Now available on demand, view our webinar with Dr. Shigeki Yagyu, M.D., Ph.D., Professor at Shinshu University. Learn about the novel development of piggyBac® transposon-based CAR T (PB CAR T) cells. A GMP-compliant manufacturing process generated CAR T cells with a predominant stem cell memory-like phenotype. PB CAR T cells demonstrated sustained anti-tumor cell killing during multiple rechallenges in vitro and debulked tumors in vivo. A clinical study of PB CAR T cells for solid tumors is underway to evaluate their safety and efficacy.
MaxCyte® Flow Electroporation Enables Immunocytokine Manufacturing
Our Chief Scientific Officer, Dr. Cenk Sumen, recently contributed to a Genetic Engineering & Biotechnology News article offering insights into transient protein expression and its ability to transform bioproduction.
Interview with Lubna Hindi, Manufacturing Engineer
In this issue, Lubna Hindi, shares with us her passion for working at MaxCyte as a Manufacturing Engineer focused on Technical Assessments. Her work in the biotech industry presents daily challenges that require-innovation and out-of-the-box thinking.
“We discussed the optimization of electroporation conditions with MaxCyte researchers...This experience helped us a lot in the development of our T cell product and we were very impressed with the kind and reliable discussions with the MaxCyte team.”